Thetis Pharmaceuticals Announces Poster Presentation at 2023 AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics (10/4/2023)
Poster to highlight preclinical data showing that TP-317 drives efficacy in solid tumors by engaging innate and adaptive anti tumor immunity in the tumor microenvironment (TME)
ESSEX, CT – (October 4, 2023) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing a first-in-class small molecule ChemR23 agonist to treat cancer and chronic inflammatory diseases, today announced that an abstract has been selected for presentation at the upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023 in Boston, MA. The poster to be presented at the conference in Poster Session A on Thursday, October 12, 12:30 pm-4:00 pm (Level 2, Exhibit Hall D),can be viewed at this link.
"In established syngeneic murine solid tumors TP 317 broadly modulates innate and adaptive immune cell compartments in the TME, consistent with resetting the immunogenic tone and favoring anti tumor immunity. RNA sequencing reveals that TP 317 upregulates MHC I/MHC II antigen presenting pathways both within the myeloid immune compartment and tumor cells, said John Parkinson, Chief Scientific Officer of Thetis Pharmaceuticals, “TP-317 is a first-in-class, small molecule drug with a novel and highly differentiated myeloid-directed mechanism of action that has transformational potential for the treatment of high unmet medical need solid tumors such as PDAC, refractory NSCLC and metastatic melanoma.”
About TP-317
Overview: TP-317 is a patented small molecule drug that delivers RvE1, an endogenous lipid mediator that regulates immune homeostasis. Unlike anti-inflammatory drugs and anti-cancer agents that are immuno-suppressive, TP-317 activates innate and adaptive immune pathways to treat disease without compromising host-protective immunity.
Cancer Program: In cancer, TP-317 is being developed as an adjunct to standard of care therapy in refractory metastatic melanoma, advanced non-small-cell lung cancer (NSCLC), and pancreatic cancer. Preclinical studies with oral TP-317 in tumor models of these cancers have shown potent single-agent activity, and enhanced efficacy when combined with immune checkpoint inhibitors or chemotherapy.
IBD Program: In IBD, TP-317 is being developed as first-line, oral therapy for mild-to-moderate Crohn’s disease and as second-line, oral therapy for mild-to-moderate ulcerative colitis in patients who are not well controlled on 5-ASA or corticosteroids. TP-317 also has potential to treat moderate-to-severe IBD as adjunct therapy to standard-of-care biologics or oral immunomodulators. The anticipated high safety premium for TP-317 further supports early intervention in IBD and other immune disorders.
About Thetis Pharmaceuticals
Thetis is a biopharmaceutical company dedicated to improving the lives of patients suffering from cancer and chronic inflammatory diseases. Thetis’ proprietary HEALER™ technology enables the pharmaceutical development of Resolvins, overcoming the stability, manufacturing, and formulation hurdles that have limited their commercial development. Thetis is supported by venture capital investors, NIH, and leading private philanthropies, including the Helmsley Charitable Trust, the Crohn’s & Colitis Foundation, and the Kenneth Rainin Foundation.
Disclaimer
TP-317 is an investigational drug product that has not been approved by the U.S. Food and Drug Administration.
Contact Information
For more information, please visit Thetis Pharmaceuticals’ website (www.thetispharma.com) or email us at info@thetispharma.com.